NeoTract says the U.S. Centers for Medicare and Medicaid Services (CMS) has okayed reimbursement for the company's UroLift System for the treatment of benign prostatic hyperplasia (BPH), or enlarged prostate.
NeoTract said the Centers for Medicare & Medicaid Services OK'd reimbursement for its UroLift system for treating benign prostatic hyperplasia, or enlarged prostate.
Coverage for the product is slated to begin Jan. 1, 2015.
from MassDevice - FDA and Medical device business news and jobs for the medical device industry http://ift.tt/10QA9i6
Cap comentari:
Publica un comentari a l'entrada